Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

European Medicines Agency

More EMA staff expected to move to Amsterdam

Fewer staff than feared will leave their jobs when the European Medicines Agency moves its headquarters to Amsterdam, it has been revealed.

Amsterdam ema building

Source: European Medicines Agency

Amsterdam will be the new home of the European Medicines Agency after Brexit

The European Medicines Agency (EMA) will lose fewer staff than feared when it moves from its London headquarters to a new home in Amsterdam after Brexit.

Europe’s drugs safety watchdog anticipated in summer 2018 that around 30% of its existing 900-strong workforce would not make the move to the Netherlands, but that figure has now been revised down to 24%.

The lower number is attributed to support on offer to those employees who want to move and “positive feedback” from those who have already set up home in Amsterdam, the EMA told The Pharmaceutical Journal.

“The numbers change on a daily basis though, as more staff make decisions as the date for relocation approaches. We are monitoring the situation closely,” a spokesperson said.

Some 60 staff have already left London in advance of moving to new temporary headquarters in Amsterdam. Others are expected to move in early 2019, ahead of the 29 March 2019 Brexit deadline; some employees have postponed their move to coincide with the new academic year starting in September 2019.

The EMA confirmed that redundancy is not being offered to staff who decide against going to Amsterdam as, under European Union (EU) staff regulations, it is not an option for employees who are requested to move to new premises.

“This principle is fundamental to the functioning of the administration of all EU bodies,” the EMA said.

Citation: Clinical Pharmacist DOI: 10.1211/PJ.2018.20205789

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Visit rpharms.com

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.